September/October 2011 Volume 4, Number 6

Chicago, IL—Similar outcomes were found with 2 different antithrombotic strategies in a comparative effec - tiveness study in patients with atrial fibrillation (AF) after a non–ST-segment elevation myocardial infarction (NSTEMI). But a trend toward more bleeding with intensified treatment was found.

Daniel G. Garrett, RPh, MS, FASHPIt is only 75 miles from Asheville, NC, to Hickory, NC.

This follow-up study was conducted to determine if a previously successful, community-based, chronic disease management model, known as the Asheville Project, could be replicated in other communities in the country.

Keeping a Lid on Health Plan Costs, One Patient at a Time

Chest pain, or angina pectoris, is the primary symptom of coronary artery disease (CAD), or chronic heart disease, a leading cause of morbidity and mortality in the United States.

Medical Claims Data Can Inform Coverage Decisions in Managed Care Health Plans

F. Randy Vogenberg, PhD, RPhChange in the marketplace cannot be stopped and, therefore, organizational development should not only reflect what is happening today but also prepare each organization to appropriately identify emerging changes in market conditions to best benefit from the opportunities for proper management and growth through change or account management.

Rhonda Greenapple, MSPHDiabetes is an important disease state causing significant morbidity and mortality throughout the United States and worldwide. The current obesity epidemic, together with the US aging population, is fueling the rapid increase in diabetes prevalence.

We Must All Engage in the Diabetes Challenge: A Lifelong Journey, with No Silver Bullet

Steve Stricker, PharmD, MS, BCOP Assistant Professor of Pharmacy Practice, Samford University McWhorter School of Pharmacy, Birmingham, ALIt is next to impossible for a day to go by without thinking about the contributions of personalized medicine to the care of patients living with cancer.

Douglas Moeller, MDPayers and providers are looking to “bundled payments” as the payment reform most likely to deliver cost-savings and drive positive outcomes. Bundled payment generally refers to a lump sum paid to providers for a predefined episode of care.

This article outlines some of the novel therapies recently approved by the US Food and Drug Administration (FDA) or are furthest along in clinical trials for type 2 diabetes.

Dipeptidyl Peptidase-4 Inhibitors

Some 13,000 healthcare professionals from around the world gathered in San Diego, CA, in June 2011 to attend the annual meeting of the American Diabetes Association. Cutting-edge research presented at the meeting included more than 2000 abstracts and 96 symposia, as well as 7 state-of-the-art lectures and 131 late-breaking posters, reflecting the growing urgency of the diabetes epidemic and the focus on improving patient care and clinical outcomes.

Results 1 - 10 of 10
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME